Ocular Therapeutix (OCUL) Change in Receivables (2013 - 2026)

Ocular Therapeutix's Change in Receivables history runs 14 years deep, the most recent figure standing at -$6.3 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 12.06% year-over-year to -$6.3 million; the TTM figure through Mar 2026 stood at -$874000.0 (up 34.04% YoY), while the FY2025 annual figure was -$1.7 million, down 127.99% from the prior year.
• Change in Receivables was -$6.3 million for Q1 2026 at Ocular Therapeutix, down from -$118000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $6.2 million in Q2 2023 to a low of -$7.2 million in Q1 2025.
• Historically, Change in Receivables has averaged $188941.2 across 5 years, with a median of $356000.0 in 2025.
• Biggest YoY gain for Change in Receivables was 11766.67% in 2025; the steepest drop was 2052.86% in 2025.
• A 5-year view of Change in Receivables shows it stood at $1.5 million in 2022, then jumped by 70.06% to $2.6 million in 2023, then fell by 16.87% to $2.2 million in 2024, then sank by 105.48% to -$118000.0 in 2025, then plunged by 5241.53% to -$6.3 million in 2026.
• The last three Change in Receivables figures came in at -$6.3 million (Q1 2026), -$118000.0 (Q4 2025), and $356000.0 (Q3 2025), per Business Quant data.